Emphasis on pleiotropic effects, a new paradigm shift?

Coronary Artery Disease

Volumn 15, Issue 5, 2004, Pages 223-225

  Davignon, Jean ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Atherosclerosis; Paradigm shift; Pleitropic effects; Statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; RAC PROTEIN; RHO FACTOR;

ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; NONHUMAN; PLEIOTROPY; PRENYLATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STROKE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 4043169945     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mca.0000131571.06897.da     Document Type: Review

References (31)

1. Wang TJ, Stafford RS, Ausiello JC, Chaisson CE. Randomized clinical trials and recent patterns in the use of statins. Am Heart J 2001; 141:957-963.
2. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. AFCAPS TexCAPS Res Grp: primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279:1615-1622.
3. Collins R, Armitage J, Parish S, Sleight P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
4. LaRosa JC. What do the statins tell us? Am Heart J 2002; 144:S21-S26.
5. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. ASCOT I - prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-1158.
6. Davignon J. Methods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects. Am J Cardiol 1998; 81:17F-23F.
7. Thompson GR, Barter PJ. Clinical lipidology at the end of the millennium. Curr Opin Lipidol 1999; 10:521-526.
8. Dujovne CA. Guidelines for clinical evaluation, development, and regulation of lipid-acting anti-atherosclerosis agents. Am J Cardiol 1998; 81:F1.
9. Nilsson J. The mevanolate pathway - a link between cellular cholesterol homeostasis and growth regulation. J Intern Med 1992; 232:10-13.
10. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21:1712-1719.
11. Neuhaus O, Archelos JJ, Hartung HP. Statins in multiple sclerosis: a new therapeutic option? Mult Scler 2003; 9:429-430.
12. Crisby M, Carlson LA, Winblad B. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2002; 16:131-136.
13. Kirsch C, Eckert GP, Mueller WE. Statin effects on cholesterol microdomains in brain plasma membranes. Biochem Pharmacol 2003; 65:843-856.
14. Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003; 170:1524-1530.
15. Wong RWK, Rabie ABM. Statin collagen grafts used to repair defects in the parietal bone of rabbits. Br J Oral Maxillofac Surg 2003; 41:244-248.
16. Meroni PL, Raschi E, Testoni C, Tincani A, Balestrieri G, Molteni R, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-β2-glycoprotein I) antibodies - effect on the pro-adhesive and pro-inflammatory phenotype. Arthritis Rheum 2001; 44:2870-2878.
17. Van de Donk NWCJ, Kamphuis MMJ, Lokhorst HM, Bloem AC. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002; 16:1362-1371.
18. Laufs U, Wassmann S, Hilgers S, Ribaudo N, Böhm M, Nickenig G. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001; 88:1306-1307.
19. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Med 2001; 7:687-692.
20. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557-1565.
21. Kayikcioglu M, Can L, Evrengul H, Payzin S, Kultursay H. The effect of statin therapy on ventricular late potentials in acute myocardial infarction. Int J Cardiol 2003; 90:63-72.
22. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92:1379-1383.
23. Aronow WS, Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol greater than or equal to 125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol 2002; 90:147-149.
24. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003; 108:839-843.
25. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality - an overview of randomized trials. JAMA 1997; 278:313-321.
26. Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on stroke prevention - a meta-analysis of randomized trials. Arch Intern Med 2003; 163:669-676.
27. Freeman DJ, Norrie J, Sattar N, Neely RDG, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus - evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103:357-362.
28. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial biology for the investigation of the treatment effects of reducing cholesterol - a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106:2055-2060.
29. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291:1071-1080.
30. Hakamada-Taguchi R, Uehara Y, Kuribayashi K, Numabe A, Saito K, Negoro H, et al. Inhibition of hydroxymethylglutaryl-coenzyme A reductase reduces Th1 development and promotes Th2 development. Circ Res 2003; 93:948-956.
31. Davignon J. The cardioprotective effects of statins. Curr Atheroscler Rep 2004; 6:27-35.